New Treatment Options for COPD: How Do We Decide Phenotypes, Endotypes or Treatable Traits?
作者信息
Balkissoon Ron
机构信息
Denver, Colorado.
出版信息
Chronic Obstr Pulm Dis. 2018 Jan 18;5(1):72-80. doi: 10.15326/jcopdf.5.1.2018.0128.
Abstract
摘要
相似文献
1
New Treatment Options for COPD: How Do We Decide Phenotypes, Endotypes or Treatable Traits?慢性阻塞性肺疾病的新治疗选择：我们如何确定表型、内型或可治疗特征？
Chronic Obstr Pulm Dis. 2018 Jan 18;5(1):72-80. doi: 10.15326/jcopdf.5.1.2018.0128.
2
Treatable traits of chronic airways disease.慢性气道疾病的可治疗特征。
Curr Opin Pulm Med. 2018 Jan;24(1):24-31. doi: 10.1097/MCP.0000000000000445.
3
Airflow obstruction: is it asthma or is it COPD?气流阻塞：是哮喘还是慢性阻塞性肺疾病？
Int J Chron Obstruct Pulmon Dis. 2016 Nov 30;11:3007-3013. doi: 10.2147/COPD.S54927. eCollection 2016.
4
[Personalised COPD care: Where are we going?].[慢性阻塞性肺疾病的个性化护理：我们将何去何从？]
Rev Pneumol Clin. 2018 Oct;74(5):315-326. doi: 10.1016/j.pneumo.2018.09.003. Epub 2018 Oct 11.
5
Neutrophil to lymphocyte ratio is a better indicator of COPD exacerbation severity in neutrophilic endotypes than eosinophilic endotypes.在嗜中性粒细胞亚型中，中性粒细胞与淋巴细胞比值比嗜酸性粒细胞亚型更能准确反映慢性阻塞性肺疾病急性加重的严重程度。
Int J Chron Obstruct Pulmon Dis. 2018 Sep 4;13:2721-2730. doi: 10.2147/COPD.S170353. eCollection 2018.
6
Precision medicine in united airways disease: A "treatable traits" approach.精准医疗在气道疾病中的应用：一种“可治疗特征”的方法。
Allergy. 2018 Oct;73(10):1964-1978. doi: 10.1111/all.13496. Epub 2018 Jul 10.
7
Proteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entities.哮喘和 COPD 表型和内型的蛋白质组学研究，用于生物标志物的发现和对疾病实体的更好理解。
J Proteomics. 2011 Dec 10;75(1):192-201. doi: 10.1016/j.jprot.2011.10.008. Epub 2011 Oct 20.
8
Asthma Phenotypes and Endotypes: Implications for Personalised Therapy.哮喘表型和内型：对个体化治疗的启示。
BioDrugs. 2017 Oct;31(5):393-408. doi: 10.1007/s40259-017-0242-5.
9
What does endotyping mean for treatment in chronic obstructive pulmonary disease?表型分型对慢性阻塞性肺疾病的治疗意味着什么？
Lancet. 2017 Sep 2;390(10098):980-987. doi: 10.1016/S0140-6736(17)32136-0.
10
Chronic obstructive pulmonary disease classification, phenotypes and risk assessment.慢性阻塞性肺疾病的分类、表型及风险评估。
J Thorac Dis. 2019 Sep;11(Suppl 14):S1761-S1766. doi: 10.21037/jtd.2019.05.10.
引用本文的文献
1
Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.靶向嗜酸性慢性阻塞性肺疾病中白细胞介素-5或白细胞介素-5受体α的单克隆抗体：一项系统评价和荟萃分析
Front Pharmacol. 2021 Nov 2;12:754268. doi: 10.3389/fphar.2021.754268. eCollection 2021.
2
Targeting IL-5 in COPD.靶向 COPD 中的 IL-5。
Int J Chron Obstruct Pulmon Dis. 2019 May 16;14:1045-1051. doi: 10.2147/COPD.S155306. eCollection 2019.
本文引用的文献
1
Triple Therapy in COPD: What We Know and What We Don't.慢性阻塞性肺疾病的三联疗法：我们所知道的和我们所不知道的。
COPD. 2017 Dec;14(6):648-662. doi: 10.1080/15412555.2017.1389875. Epub 2017 Nov 9.
2
Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.中重度气流受限 COPD 患者使用糠酸氟替卡松/维兰特罗吸入剂的肺炎风险：SUMMIT 研究。
Respir Med. 2017 Oct;131:27-34. doi: 10.1016/j.rmed.2017.07.060. Epub 2017 Aug 1.
3
Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.慢性阻塞性肺疾病患者的加重频率：SPIROMICS 队列分析。
Lancet Respir Med. 2017 Aug;5(8):619-626. doi: 10.1016/S2213-2600(17)30207-2. Epub 2017 Jun 28.
4
Run-in bias in randomised trials: the case of COPD medications.随机试验中的导入期偏倚：慢性阻塞性肺疾病药物的案例
Eur Respir J. 2017 Jun 22;49(6). doi: 10.1183/13993003.00361-2017. Print 2017 Jun.
5
A Light in the Darkness? The FLAME Trial, Blood Eosinophils, and Chronic Obstructive Pulmonary Disease.黑暗中的一丝曙光？FLAME试验、血液嗜酸性粒细胞与慢性阻塞性肺疾病
Am J Respir Crit Care Med. 2017 May 1;195(9):1125-1127. doi: 10.1164/rccm.201703-0560ED.
6
Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma.嗜酸性慢性阻塞性肺疾病（COPD）与有哮喘病史的COPD患者的临床特征
Respir Res. 2017 Apr 26;18(1):73. doi: 10.1186/s12931-017-0559-0.
7
Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病中的嗜酸性粒细胞增多、频繁加重及类固醇反应
Am J Respir Crit Care Med. 2017 Nov 1;196(9):1219-1221. doi: 10.1164/rccm.201612-2525LE.
8
Pharmacological treatment for COPD; GOLD 2017 changes direction.慢性阻塞性肺疾病的药物治疗；《慢性阻塞性肺疾病全球倡议（GOLD）2017》改变方向。
Br J Clin Pharmacol. 2017 May;83(5):935-937. doi: 10.1111/bcp.13212. Epub 2017 Mar 9.
9
Indacaterol-Glycopyrronium for COPD.茚达特罗-格隆溴铵用于慢性阻塞性肺疾病
N Engl J Med. 2016 Sep 1;375(9):899-900. doi: 10.1056/NEJMc1609305.
10
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.使用乌美溴铵/维兰特罗预防慢性阻塞性肺疾病的临床重要恶化。
Int J Chron Obstruct Pulmon Dis. 2016 Jun 24;11:1413-24. doi: 10.2147/COPD.S101612. eCollection 2016.
Zotero 插件